Bloomberg, April 15, 2024: Since 2014, pharmaceutical companies have made over $3.6 billion from FDA-approved drugs that were later withdrawn or proven ineffective. This news article explores how fast-track approvals may prioritize speed over efficacy, wasting your money and not helping you fight serious diseases.
Read More »Author: Caroline Bradford
Guest Lecture by Diana Zuckerman for Georgetown University Grad Students
April 10, 2024: NCHR president Diana Zuckerman gave a guest lecture to Georgetown University grad students discussing the lead, PFAS, EDCs, and other carcinogens and toxic materials in artificial turf, rubber playground surfaces, and recycled tire tiles & mulch that are used at homes, schools, and daycare centers. This is the text of that lecture, with photos from the PowerPoint slides.
Read More »Letter to Sen. Sanders in Support of the Childhood Diabetes Reduction Act
April 12, 2024: This bill takes important steps to adequately inform consumers about the known risks of foods marketed to children and often consumed by all family members
Read More »10 doctors on FDA panel for Abbott heart device had financial ties to the company. The FDA didn’t disclose the payments.
NBC News and Kaiser Health News, April 6, 2024: NBC News reported the Kaiser Health News investigation showing that 10 doctors who advised FDA about Abbott’s heart device TriClip had financial ties to the company that weren’t disclosed. Their votes almost unanimously supported approval. We explain that FDA conflict of interest rules are too loose.
Read More »Scientists urge FDA to rescind approval of test for opioid addiction risk
Washington Post, April 5, 2024: NCHR president is one of 31 scientists urging FDA to rescind approval of AvertD DNA test that purports to predict risk of opioid addiction and urging CMS to refuse to pay for the test because it does not work and can do more harm than good.
Read More »